TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Aligos Therapeutics ( (ALGS) ) is now available.
On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ALGS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.
Spark’s Take on ALGS Stock
According to Spark, TipRanks’ AI Analyst, ALGS is a Neutral.
The overall stock score for Aligos Therapeutics is primarily impacted by its weak financial performance and negative valuation metrics, indicating significant profitability challenges. Technical analysis provides some positive short-term signals, but long-term trends remain weak.
To see Spark’s full report on ALGS stock, click here.
More about Aligos Therapeutics
Average Trading Volume: 157,738
Technical Sentiment Signal: Sell
Current Market Cap: $46.66M
Find detailed analytics on ALGS stock on TipRanks’ Stock Analysis page.